Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dustin Fontenot

Physician Assistant Round Rock, TX Physician Assistant

NPI 1508046715 CMS profile 10826896

970 Hesters Crossing Rd, Suite 101, Round Rock, TX 78681

Open in the dashboard

General payments

$46,767

343 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dustin Fontenot of Round Rock, TX is reported in the CMS Open Payments database as having received $46,767 across 343 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,352 62
2024 General $20,603 120
2023 General $11,036 67
2022 General $5,900 61
2021 General $876 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dustin Fontenot
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Dustin Fontenot were reported at $8,352. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Dustin Fontenot Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $876 $132 $37–$438 $132
2022 $5,900 $155 $48–$522 $149
2023 $11,036 $167 $52–$557 $160
2024 $20,603 $178 $55–$600 $164
2025 $8,352 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axonics Modulation Technologies, Inc. $34,861 179 payments
  2. Boston Scientific Corporation $6,943 29 payments
  3. Coloplast Corp $1,960 12 payments
  4. 180 Medical, Inc. $400 10 payments
  5. Endo Pharmaceuticals Inc. $261 18 payments
  6. Novo Nordisk Inc $223 6 payments
  7. Clarus Therapeutics Inc. $191 9 payments
  8. Progenics Pharmaceuticals, Inc. $157 2 payments
  9. Antares Pharma, Inc. $155 9 payments
  10. Astellas Pharma US Inc $135 3 payments
  11. Other $1,482 66 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $19,323 13 payments
  2. Travel and Lodging $14,062 72 payments
  3. Food and Beverage $9,798 248 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,484 9 payments
  5. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. Axonics Urology $37,856 191 payments
  2. Axonics Axonics - Torque Wrench - URO $3,484 9 payments
  3. Titan $1,901 9 payments
  4. XIAFLEX $349 22 payments
  5. Bulkamid $315 5 payments
  6. AVEED $313 20 payments
  7. Axonics r-SNM System $273 4 payments
  8. XYOSTED $210 12 payments
  9. EDEX $196 14 payments
  10. JATENZO $191 9 payments
  11. Other $2,585 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

497

Median for Physician Assistant: 241

Drug cost

$57,201

Median for Physician Assistant: $4,110

Branded share of claims

36.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 32 $22,015
Myrbetriq Mirabegron Brand 27 $20,999
Xyosted Testosterone Enanthate Brand 11 $6,460
Testosterone Cypionate Generic 60 $3,119
Tamsulosin Hcl Generic 97 $1,055
Alfuzosin Hcl Er Alfuzosin Hcl Brand 55 $1,004
Trospium Chloride Generic 22 $819
Tadalafil Generic 14 $560
Solifenacin Succinate Generic 25 $519
Finasteride Generic 16 $235

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYOSTED
  • Antares Pharma, Inc. $61
$61 11 —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $43
$43 — —
JELMYTO
  • UROGEN PHARMA, INC. $41
$41 — —
BOTOX
  • AbbVie, Inc. $27
$27 — —
XIAFLEX
  • Endo USA, Inc. $17
  • Endo Pharmaceuticals Inc. $8
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

343 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record